52 North

52North, also known as 52 North Health Ltd., is a medical technology company based in Cambridge, UK. Founded in 2018 as a spin-out from the University of Cambridge, the company specializes in innovative in-vitro diagnostic devices and digital solutions aimed at improving emergency care for cancer patients at risk of neutropenic sepsis. The company's flagship technology is the patented Aster™ platform, which is the first portable system for cell measurement. This platform allows for rapid multiplexing of cell-based and soluble biomarkers from a single finger-prick blood sample. Key products include NeutroCheck®, a point-of-care diagnostic device that measures neutrophil levels and sepsis markers, and a digital triaging tool designed to help manage emergency cancer care needs remotely. 52North's mission focuses on enhancing patient safety and quality of life while reducing healthcare costs through home-based testing solutions.